Our priority is to support you
and your patients
ELIGARD (leuprorelin acetate) is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.1
Choose ELIGARD for your eligible patients with prostate cancer.1
Stable, long-term
ADT patients
- ADT for 6+ months
- Low complication risk
- Fewer injections vs 3-monthly dosing
Patients
with mobility
or access
challenges
- Frail, elderly
or rural - Fewer injections vs 3-monthly dosing
Men who
need stable
T suppression
- High-risk disease
- Stable on 3-month ADT
- At risk of missed dose rebound
- Full-time or
shift work - Minimise time
off work - Convenience
when travelling
Patients
who want
convenience
- Fewer injections vs 3-monthly dosing
- Primary care
appointments
Patients with
injection anxiety or discomfort
- Needle-phobic patients
- Poor IM tolerability
- Prefers SC route/improved
experience - Primary care
management
ADT, androgen deprivation therapy; IM, intramuscular; SC, subcutaneous